Qlife Holding AB (publ)

Stockholm Stock Exchange QLIFE.ST

Qlife Holding AB (publ) Revenue for the year ending December 31, 2023: USD 24.08 K

Qlife Holding AB (publ) Revenue is USD 24.08 K for the year ending December 31, 2023, a -98.60% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Qlife Holding AB (publ) Revenue for the year ending December 31, 2022 was USD 1.72 M, a -60.60% change year over year.
Qlife Holding AB (publ) Revenue for the year ending December 31, 2021 was USD 4.36 M, a 73.42% change year over year.
Qlife Holding AB (publ) Revenue for the year ending December 31, 2020 was USD 2.51 M, a 103.48% change year over year.
Qlife Holding AB (publ) Revenue for the year ending December 31, 2019 was USD 1.24 M.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Stockholm Stock Exchange: QLIFE.ST

Qlife Holding AB (publ)

CEO	Mr. Thomas Warthoe
IPO Date	March 2, 2020
Location	Sweden
Headquarters	Redaregatan 48
Employees	24
Sector	Health Care
Industries Pharmaceuticals Biotechnology Medical Instruments

Description

Qlife Holding AB (publ), a med-tech company, manufactures and sells in-vitro diagnostic analyzers and reagents. The company offers Egoo.Health Platform, an integrated platform with a measuring instrument with disposable capsules and software, where each capsule contains a test for a specific biomarker or virus. Its biomarkers include C-reactive protein home-testing capsule, PHE/Phenylalanine for PKU patients, and Sars-CoV-2/Influenza multiplex for virus/bacteria tests. The company was incorporated in 2019 and is based in Helsingborg, Sweden.

Key trends

Past 5 years